Clinical trials
Immune System Diseases trials in the United States with no applicable phase
Search ClinicalTrials.gov registrations by keyword, then narrow by condition, phase, status, country and start year.
28 trials match Source: ClinicalTrials.gov registrations
Trials started per year
By phase, 2000 to 2026.
| Category | Trials |
|---|---|
| 2000 | 4 |
| 2002 | 1 |
| 2005 | 1 |
| 2010 | 2 |
| 2012 | 3 |
| 2013 | 1 |
| 2015 | 1 |
| 2016 | 2 |
| 2017 | 2 |
| 2018 | 1 |
| 2019 | 1 |
| 2022 | 2 |
| 2023 | 2 |
| 2026 | 1 |
Status
Trials by registry status. Select a bar to filter.
| Category | Trials |
|---|---|
| Completed | 22 |
| Recruiting | 2 |
| Terminated | 2 |
| Unknown status | 2 |
Top lead sponsors
A sponsor with a page on Pharma Observatory links to it.
| Category | Trials |
|---|---|
| Fairview University Medical Center | 3 |
| National Center for Research Resources (NCRR) | 3 |
| Appalachian State University | 2 |
| University of Texas at Austin | 2 |
| Albert Einstein College of Medicine | 1 |
| Big Bold Health, PBC | 1 |
| California Department of Health Services | 1 |
| Columbia University | 1 |
| David Van Sickle | 1 |
| Emory University | 1 |
Top conditions
MeSH conditions the trials were registered with, not their broader categories. A condition with a page on Pharma Observatory links to it.
| Category | Trials |
|---|---|
| Immune System Diseases | 28 |
| Communicable Diseases | 8 |
| Rare Diseases | 8 |
| Autoimmune Diseases | 6 |
| Lupus Erythematosus, Systemic | 5 |
| Arthritis | 4 |
| Connective Tissue Diseases | 4 |
| Hypersensitivity | 4 |
| Hypersensitivity, Immediate | 4 |
| Respiratory Tract Diseases | 4 |
Trials
Showing 1 to 25 of 28. Each trial links to its page on Pharma Observatory.
Recently changed trials
Changes observed in the last 7 days, newest first, site-count changes left out. Source: ClinicalTrials.gov.
No changes to these trials in the last 7 days.
Go deeper on Pharma Observatory
Pharma Observatory connects clinical trials, sponsors, sites and investigators in one searchable platform.